Latest schizophrenia Stories

Johns Hopkins study links 1 family's rare gene mutation to brain cell abnormality and mental illness Johns Hopkins researchers have identified a rare gene mutation in a single family with a high rate of schizophrenia, adding to evidence that abnormal genes play a role in the development of the disease. The researchers, in a report published in the journal Molecular Psychiatry, say that family members with the mutation in the gene Neuronal PAS domain protein 3 (NPAS3) appear at high risk...

University of Colorado researchers study choline in infants Choline, an essential nutrient similar to the B vitamin and found in foods such as liver, muscle meats, fish, nuts and eggs, when given as a dietary supplement in the last two trimesters of pregnancy and in early infancy, is showing a lower rate of physiological schizophrenic risk factors in infants 33 days old. The study breaks new ground both in its potentially therapeutic findings and in its strategy to target markers of...

Some brain changes that are found in adults with common gene variants linked to disorders such as Alzheimer's disease, schizophrenia, and autism can also be seen in the brain scans of newborns. "These results suggest that prenatal brain development may be a very important influence on psychiatric risk later in life," said Rebecca C. Knickmeyer, PhD, lead author of the study and assistant professor of psychiatry in the University of North Carolina School of Medicine. The study was published...

Lawrence LeBlond for redOrbit.com - Your Universe Online Domestic violence (DV) can be emotionally scarring no matter who is involved, but some may be more prone to it than others, according to a new study. Those with mental health disorders are more likely to have experienced domestic violence than the general population, say researchers from King’s College London’s Institute of Psychiatry and University of Bristol. Their study follows previous research showing a link between DV...

MOUNTAIN VIEW, Calif., Dec. 21, 2012 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the U.S. Food and Drug Administration (FDA) approved ADASUVE(®) (loxapine) Inhalation Powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. ADASUVE combines Alexza's proprietary Staccato(®) delivery system with the antipsychotic drug, loxapine. The Staccato system is a hand-held inhaler that delivers a drug...

SAN DIEGO, Dec. 18, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase IIb clinical trial (Kinect 2 Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The design of this six-week Phase IIb study is a randomized, parallel, double-blind, placebo-controlled, dose titration trial of 90 subjects with moderate to severe tardive dyskinesia and underlying mood disorders, gastrointestinal disorders,...

MOUNTAIN VIEW, Calif. and BARCELONA, Spain, Dec. 14, 2012 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending that ADASUVE (Staccato loxapine) be granted European Union (EU) centralized marketing authorization. The CHMP recommends that ADASUVE be authorized in the EU for the rapid...

SEATTLE, Dec. 6, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced promising data from the single-ascending-dose (SAD) study portion of the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease. In this successful...

Researchers at the University of California, San Diego School of Medicine and the VA San Diego Healthcare System have found that deficiencies in the neural processing of simple auditory tones can evolve into a cascade of dysfunctional information processing across wide swaths of the brain in patients with schizophrenia. The findings are published in the current online edition of the journal Neuroimage. Schizophrenia is a mental disorder characterized by disturbed thought processes and...

WELWYN GARDEN CITY, England and BOSTON, November 30, 2012 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery company, is delighted to announce that its Chief Scientific Officer and founder, Fiona Marshall, has received a 2012 Women of Outstanding Achievement Award from WISE, a UK national campaign to promote female talent in science, engineering, technology and the built environment. Dr Marshall received the award in the Innovation and Entrepreneurship...